{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:57:58Z","timestamp":1789891078766,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,29]],"date-time":"2012-09-29T00:00:00Z","timestamp":1348876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00280-012-1972-1","type":"journal-article","created":{"date-parts":[[2012,9,30]],"date-time":"2012-09-30T12:32:02Z","timestamp":1349008322000},"page":"53-62","source":"Crossref","is-referenced-by-count":19,"title":["Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2\/neu overexpressing breast cancer: EORTC study 16023"],"prefix":"10.1007","volume":"71","author":[{"given":"Bojana Milojkovic","family":"Kerklaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja","family":"Mergui-Roelvink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Marreaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Govaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,29]]},"reference":[{"issue":"4905","key":"1972_CR1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712","journal-title":"Science"},{"issue":"8","key":"1972_CR2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1634\/theoncologist.10-8-565","volume":"10","author":"NM Appels","year":"2005","unstructured":"Appels NM, Beijnen JH, Schellens JH (2005) Development of farnesyl transferase inhibitors: a review. Oncologist 10(8):565\u2013578","journal-title":"Oncologist"},{"issue":"5","key":"1972_CR3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1158\/1535-7163.MCT-09-0833","volume":"9","author":"M Geryk-Hall","year":"2010","unstructured":"Geryk-Hall M, Yang Y, Hughes DP (2010) Driven to death: inhibition of farnesylation increases Ras activity in osteosarcoma and promotes growth arrest and cell death. Mol Cancer Ther 9(5):1111\u20131119","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1972_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J, Targeting RAS (2003) Signalling pathways in cancer therapy. Nat Rev Cancer 3(1):11\u201322","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1972_CR5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/jcb.21028","volume":"99","author":"J Wesierska-Gadek","year":"2006","unstructured":"Wesierska-Gadek J, Kramer M, Schmid G (2006) Prevention of farnesylation of c-Ha-Ras protein enhances synergistically the cytotoxic action of doxorubicin in cycling but not in quiescent cells. J Cell Biochem 99(6):1664\u20131676","journal-title":"J Cell Biochem"},{"issue":"1","key":"1972_CR6","first-page":"112","volume":"6","author":"CA Smith","year":"2000","unstructured":"Smith CA, Pollice AA, Gu LP, Brown KA, Singh SG, Janocko LE, Johnson R, Julian T, Hyams D, Wolmark N, Sweeney L, Silverman JF, Shackney SE (2000) Correlations among p53, Her-2\/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 6(1):112\u2013126","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1972_CR7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11912-003-0096-5","volume":"5","author":"C Baum","year":"2003","unstructured":"Baum C, Kirschmeier P (2003) Preclinical and clinical evaluation of farnesyltransferase inhibitors. Curr Oncol Rep 5(2):99\u2013107","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1972_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1194\/jlr.R500012-JLR200","volume":"47","author":"AD Basso","year":"2006","unstructured":"Basso AD, Kirschmeier P, Bishop WR (2006) Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47(1):15\u201331","journal-title":"J Lipid Res"},{"issue":"19","key":"1972_CR9","doi-asserted-by":"crossref","first-page":"16161","DOI":"10.1074\/jbc.M006213200","volume":"276","author":"NC Crespo","year":"2001","unstructured":"Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM (2001) The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276(19):16161\u201316167","journal-title":"J Biol Chem"},{"issue":"6","key":"1972_CR10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/bcr947","volume":"6","author":"J Head","year":"2004","unstructured":"Head J, Johnston SR (2004) New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res 6(6):262\u2013268","journal-title":"Breast Cancer Res"},{"issue":"19","key":"1972_CR11","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2006.05.9808","volume":"24","author":"EK Rowinsky","year":"2006","unstructured":"Rowinsky EK (2006) Lately, it occurs to me what a long, strange trip it\u2019s been for the farnesyltransferase inhibitors. J Clin Oncol 24(19):2981\u20132984","journal-title":"J Clin Oncol"},{"issue":"18","key":"1972_CR12","first-page":"5656","volume":"63","author":"TB Brunner","year":"2003","unstructured":"Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ (2003) Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 63(18):5656\u20135668","journal-title":"Cancer Res"},{"issue":"21","key":"1972_CR13","first-page":"4947","volume":"58","author":"M Liu","year":"1998","unstructured":"Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR (1998) Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58(21):4947\u20134956","journal-title":"Cancer Res"},{"issue":"2","key":"1972_CR14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00280-010-1488-5","volume":"67","author":"C Castaneda","year":"2011","unstructured":"Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros WP, Zhu Y, Statkevich P, Cutler DL, Hurwitz HI (2011) Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemother Pharmacol 67(2):455\u2013463","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1972_CR15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2001.19.4.1167","volume":"19","author":"FA Eskens","year":"2001","unstructured":"Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M (2001) Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19(4):1167\u20131175","journal-title":"J Clin Oncol"},{"key":"1972_CR16","doi-asserted-by":"crossref","unstructured":"Kauh J, Chanel-Vos C, Escuin D, Fanucchi MP, Harvey RD, Saba N, Shin DM, Gal A, Pan L, Kutner M, Ramalingam SS, Bender L, Marcus A, Giannakakou P, Khuri FR (2011) Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer 117(17):4049\u20134059","DOI":"10.1002\/cncr.26004"},{"issue":"11","key":"1972_CR17","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.24644","volume":"125","author":"G Liu","year":"2009","unstructured":"Liu G, Taylor SA, Marrinan CH, Hsieh Y, Bishop WR, Kirschmeier P, Long BJ (2009) Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. Int J Cancer 125(11):2711\u20132720","journal-title":"Int J Cancer"},{"issue":"17","key":"1972_CR18","doi-asserted-by":"crossref","first-page":"8838","DOI":"10.1158\/0008-5472.CAN-06-0699","volume":"66","author":"AI Marcus","year":"2006","unstructured":"Marcus AI, O\u2019Brate AM, Buey RM, Zhou J, Thomas S, Khuri FR, Andreu JM, Diaz F, Giannakakou P (2006) Farnesyltransferase inhibitors reverse taxane resistance. Cancer Res 66(17):8838\u20138846","journal-title":"Cancer Res"},{"issue":"4","key":"1972_CR19","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1073\/pnas.95.4.1369","volume":"95","author":"MM Moasser","year":"1998","unstructured":"Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N (1998) Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 95(4):1369\u20131374","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"1972_CR20","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2003.12.109","volume":"21","author":"B Leyland-Jones","year":"2003","unstructured":"Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21(21):3965\u20133971","journal-title":"J Clin Oncol"},{"issue":"11","key":"1972_CR21","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.1993.11.11.2127","volume":"11","author":"MT Huizing","year":"1993","unstructured":"Huizing MT, Keung AC, Rosing H, van der Kuij V, Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11(11):2127\u20132135","journal-title":"J Clin Oncol"},{"issue":"1","key":"1972_CR22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/phrs.1999.0477","volume":"40","author":"VR Panday","year":"1999","unstructured":"Panday VR, Bokkel Huinink WW, Vermorken JB, Rosing H, Koopman FJ, Swart M, Schellens JH, Beijnen JH (1999) Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. Pharmacol Res 40(1):67\u201374","journal-title":"Pharmacol Res"},{"issue":"1","key":"1972_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1470-2045(00)00191-1","volume":"2","author":"SR Johnston","year":"2001","unstructured":"Johnston SR (2001) Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2(1):18\u201326","journal-title":"Lancet Oncol"},{"issue":"4","key":"1972_CR24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/dmd.105.007906","volume":"34","author":"A Ghosal","year":"2006","unstructured":"Ghosal A, Chowdhury SK, Tong W, Hapangama N, Yuan Y, Su AD, Zbaida S (2006) Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos 34(4):628\u2013635","journal-title":"Drug Metab Dispos"},{"issue":"2 Pt 1","key":"1972_CR25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1158\/1078-0432.CCR-06-1262","volume":"13","author":"NE Ready","year":"2007","unstructured":"Ready NE, Lipton A, Zhu Y, Statkevich P, Frank E, Curtis D, Bukowski RM (2007) Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. Clin Cancer Res 13(2 Pt 1):576\u2013583","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1972_CR26","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/1078-0432.CCR-03-0412","volume":"10","author":"FR Khuri","year":"2004","unstructured":"Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK (2004) Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10(9):2968\u20132976","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1972_CR27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/cncr.21188","volume":"104","author":"ES Kim","year":"2005","unstructured":"Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR (2005) Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory\/resistant nonsmall cell lung carcinoma. Cancer 104(3):561\u2013569","journal-title":"Cancer"},{"issue":"8","key":"1972_CR28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","volume":"22","author":"E Cutsem Van","year":"2004","unstructured":"Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y (2004) Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22(8):1430\u20131438","journal-title":"J Clin Oncol"},{"issue":"12","key":"1972_CR29","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/sj.bjc.6604402","volume":"98","author":"NM Appels","year":"2008","unstructured":"Appels NM, Bolijn MJ, Chan K, Stephens TC, Hoctin-Boes G, Middleton M, Beijnen JH, de Bono JS, Harris AL, Schellens JH (2008) Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br J Cancer 98(12):1951\u20131958","journal-title":"Br J Cancer"},{"issue":"22","key":"1972_CR30","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","volume":"272","author":"DB Whyte","year":"1997","unstructured":"Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272(22):14459\u201314464","journal-title":"J Biol Chem"},{"issue":"7","key":"1972_CR31","doi-asserted-by":"crossref","first-page":"e22769","DOI":"10.1371\/journal.pone.0022769","volume":"6","author":"F Janku","year":"2011","unstructured":"Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R (2011) PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 6(7):e22769","journal-title":"PLoS ONE"},{"issue":"41","key":"1972_CR32","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1038\/onc.2008.247","volume":"27","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Pandolfi PP (2008) The PTEN-PI3\u00a0K pathway: of feedbacks and cross-talks. Oncogene 27(41):5527\u20135541","journal-title":"Oncogene"},{"key":"1972_CR33","doi-asserted-by":"crossref","unstructured":"Piccart M (2006) Breast cancer management and molecular medicine: towards tailored approaches. Springer, Heidelberg","DOI":"10.1007\/978-3-540-28266-2"},{"issue":"9","key":"1972_CR34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1634\/theoncologist.10-9-665","volume":"10","author":"A Eniu","year":"2005","unstructured":"Eniu A, Palmieri FM, Perez EA (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10(9):665\u2013685","journal-title":"Oncologist"}],"updated-by":[{"DOI":"10.1007\/s00280-012-2064-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T00:00:00Z","timestamp":1358467200000}}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1972-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1972-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:23Z","timestamp":1559038283000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1972-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["1972"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1972-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00280-012-2064-y","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,29]]}}}